



eCAM benefits from diversity that derives from CAM
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‘Diversity’ is now a magic word, showing up everywhere and
often used to embrace many aspects of human activity,
whether in government, the arts, sciences, research, choice of
research subjects or so on. In many respects diversity repre-
sents an encompassing teamwork, and we all know the success
of teams in sports in popular terms and the rewards of success-
ful research teams. Thus, we can safely conclude that a diverse
team can be a creative team since when investigators of differ-
ent points of view are brought together, they ponder and ques-
tion the interpretations, procedures and practices of others.
Such is the case for the scientific approach (1). Thus, often
butting heads, sometimes even locking horns in healthy
debate, is most often resolved by the emergence of creativity.
I will now propose several ways in which eCAM approaches
the question of diversity and I hope that in the process we
also engage in this act of creation.
First, the editorial board of eCAM is one that is diverse, and
to ensure one aspect of creativity, many of us have never
worked together, thus allowing for the infusion of different
points of view. Our first purpose in establishing the eCAM
editorial board has been to gather a mixture of experienced
biomedical scientists and to combine them with newcomers
from a variety of fields who are willing to embrace CAM
and to extend themselves beyond their better known academic
classifications or ‘pigeonholes’. As one of our bases is in
Japan, our search for diversity began in Asia at biomedical
conferences and research centers in Japan, Taiwan, Korea,
India, China, Hong Kong and Thailand, at the same time visit-
ing similar events and places in Mexico, Venezuela, Brazil,
Europe and the United States. And these journeys were just
the beginning; we are now in the planning stages for increased
involvement in South America, the Middle East and the
African continent. In our official letter inviting scholars to
join our board, we include the following words: ‘CAM is a
worldwide phenomenon and eCAM will seek to be inclusive
of new and old work all over the globe. With this same broad
view, we envision an active and varied Editorial Board on
which philosophers and historians will be engagedin dialogues
with neuroscientists, immunologists, practitioners and clini-
cians.’ To date, the editorial board numbers about 75 members,
who reside in most of the continents and many countries. What
are most important are not so much the numbers as the disci-
plines that they embrace, and the list is ever extending into
new and exciting areas of CAM. Clearly the crucial functions
of editorial board members are threefold: submitting their
own manuscripts, critically reviewing papers and recruiting
papers. Their voices as contributors and referees have been
critical in establishing the unique worldview that can be found
in each issue of eCAM.
As one peruses our disciplines there is, to be sure, a seeming
focus on immunology—but not to the exclusion of other disci-
plines. Thus, the triangle of the three regulatory systems
(nervous–endocrine–immune) is not so evenly distributed,
but at least the immunologists realize the intimate connected-
ness of this triumvirate. Going beyond one’s usual classifica-
tion is best exemplified by invertebrate immunologists (2,3),
who bring fresh notions of using animal products as prime tar-
gets from which newer technologies can be applied to CAM.
Molecular approaches based upon antimicrobial peptides pro-
mise to add to the emerging bioprospecting compendium,
moving it from the realm of invertebrate immunology to the
CAM sector (4–6). (There was already a historical precedent
for using products from snails (7).) Moving to the apiary, bio-
logists who look at products from honeybees are already
known internationally (8–12). The lesson to be learned and
eventually put into practice concerns a wider approach to a
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diverse terrestrial and marine sources (13–16). There is even
room to consider a diverse array of complex derivatives from
certain vertebrates such as snakes (17). Botanists (qua ethno-
botanists, herbalists) have already made their mark, especially
as they literally dig up more mushrooms and cultivate diverse
plants (11,12,18–23).
Second, the other essential ingredient for successful eCAM
diversity is the inclusion of experienced, recognized biomedi-
cal scientists who are bona fide members of the CAM commu-
nity and who are open to embracing somewhat tangential
approaches that prescience reveals will be fruitful paths to
follow. These two tracks—especially this second—should
guard against the rather natural tendency of people of like
kind (educational background, use of similar techniques etc.)
to want to work with their long-term colleagues, i.e. people
with whom they have associated before or have often been
seen at meetings. Couple these two strategies with an emphasis
on the inclusion of newer technologies with the insistence on
evidence and we have designed a formula that should remove
some of the shroud around CAM, thus giving it a greater
measure of acceptance within the western medical community
and even the CAM community itself. All eCAM is doing is
redirecting biomedical scientists well known in one discipline
into thinking about the utility of their work and its applicability
to another discipline. In my view, this is the creative thought
and work that is needed to bring CAM into the arena of
western medicine.
Third, of course, recognizing and emphasizing diversity
seems only natural since the very discipline of CAM is itself
diverse, complex and controversial. It includes such diverse
disciplines as osteopathy, homeopathy, chiropractic, acupunc-
ture, herbal medicine, energy medicine and meditation, which
are associated with the ancient approaches of China, India,
Japan and Korea. Clearly other ancient cultures have much to
offer and will, we hope, be uncovered as we delve deeper
into practices in other parts of the world, such as Latin
America, the Middle East, North America and the south
Pacific, that have not been so popularized. Some of the latter,
less publicized ways of doing things from these regions could
well coincide with those from ancient Asia, differing only as a
result of the available natural products. In other words, plants
or animal products may differ but offer similar remedies for
similar health problems. Thus, remedies may to some extent
be intertwined culturally and geographically. In every instance
barring cultural and geographical lumping together, all have
been concerned with improving the quality of life.
Finally, despite these examples of diversity in numbers, geo-
graphical origins and disciplines and scientific approach, there
is the difficulty of reconciling the very nature of CAM with
certain realities, i.e. the palpable need to undergird CAM
with evidence-based results that can, through rigor, occupy
the pinnacle of the experimental triangle devoted to immuno-
logical benefits as proposed by Goldrosen and Strauss (24).
For, as has been pointed out in previous editorials, there is a
need for rigorous science if CAM and indeed eCAM are to be
taken more seriously, thus ensuring less skepticism from its
adherents and disciples and also from the traditional medical
establishment and pharmaceutical industry. Now and in the
near future, eCAM is discussing ways to consider seriously
case reports, not the ideal within an acceptable scientific
context. An excellent example devoted to Alzheimer’s disease
has led the way (25).
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